Inolitazone is primarily researched for its potential therapeutic applications in the treatment of cancer. It functions as a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, which plays a role in regulating cell growth, differentiation, and apoptosis. This mechanism makes it a candidate for targeting certain types of cancers, particularly those where PPARγ activation can inhibit tumor progression. Studies have explored its efficacy in reducing tumor growth and inducing cancer cell death in preclinical models. Additionally, its anti-inflammatory properties are being investigated for potential use in managing conditions associated with chronic inflammation. Research is ongoing to further understand its full therapeutic potential and safety profile.